RTW Funds report 9.99% stake in Stoke Therapeutics
RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G/A reporting shared beneficial ownership of 5,940,866 shares of Stoke Therapeutics common stock, representing 9.99% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G/A reporting shared beneficial ownership of 5,940,866 shares of Stoke Therapeutics common stock, representing 9.99% of the class. The filing states this percent assumes exercise of 317,341 warrants and uses February 28, 2026 as the as of date for 59,150,790 shares outstanding. The Reporting Persons disclose shared voting and dispositive power over the reported shares and note that RTW Funds, including RTW Master Fund Ltd., have the right to receive dividends or sale proceeds.
Insights
RTW reports a near-10% shared stake via funds and the CIO.
RTW Investments and Dr. Roderick Wong report shared ownership of 5,940,866 shares, equal to 9.99%, calculated on February 28, 2026 with assumed exercise of 317,341 warrants. The filing attributes voting and dispositive power as shared rather than sole.
Cash‑flow treatment and any planned disposition are not stated in the excerpt; future filings would disclose transactions if holders trade. The immediate investor takeaway is an identified large, shared position that may influence governance or liquidity depending on later actions.
Shared power and fund-level ownership are emphasized; an RTW fund holds >5%.
The filing specifies that the RTW Funds have the right to receive dividends or proceeds and that RTW Master Fund Ltd. holds more than 5% of the class. Voting and dispositive powers are reported as shared for both Reporting Persons.
Because the position is reported on a Schedule 13G/A, the disclosure signals passive institutional ownership reporting rather than an active Section 13(d) acquisition. Subsequent Form 13D/4 filings would be required if the intent or control status changes.
Key Figures
Key Terms
Warrants financial
Beneficially owned regulatory
Schedule 13G/A regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does RTW Investments report in Stoke Therapeutics (STOK)?
Are warrants included in RTW's reported ownership for STOK?
Is this Schedule 13G/A indicative of an activist intent for STOK?
AI-generated analysis. How Rhea-AI works. Not financial advice.